Display options
Share it on

Iran Red Crescent Med J. 2013 Dec;15(12):e12260. doi: 10.5812/ircmj.12260. Epub 2013 Dec 05.

Management of Bleeding in Post-liver Disease, Surgery and Biopsy in Patients With High Uncorrected International Normalized Ratio With Prothrombin Complex Concentrate: An Iranian Experience.

Iranian Red Crescent medical journal

Alireza Parand, Naser Honar, Khashayar Aflaki, Mohammad Hadi Imanieh, Mahmood Haghighat, Nader Cohan, Sezaneh Haghpanah, Marco Marietta, Zahra Serati, Saeedeh Haghbin, Mehran Karimi

Affiliations

  1. Iranian Hospital, Dubai, UAE ; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
  2. Pediatrics Gastroenterology Department, Shiraz University of Medical Sciences, Shiraz, IR Iran.
  3. Pediatric Intensive Care Unit, Shiraz University of Medical Sciences, Shiraz, IR Iran.
  4. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran.
  5. Department of Hematology, University Hospital of Modena, Modena, Italy.

PMID: 24693388 PMCID: PMC3955503 DOI: 10.5812/ircmj.12260

Abstract

BACKGROUND: To evaluate the efficacy of prothrombin complex concentrate (PCC) in the management of bleeding in patients with liver disease and patients undergoing surgery or biopsy who had a high uncorrected international normalized ratio (INR).

OBJECTIVES: In this study, we examined an Iranian sample and investigated the efficacy of PCC to manage bleeding in patients with liver disease and also patients with high uncorrected INR who were scheduled for surgery or biopsy.

MATERIALS AND METHODS: A total of 25 patients including 16 patients with post-liver disease bleeding (group 1) and 9 patients with high uncorrected INR who were scheduled for surgery or biopsy (group 2) were enrolled. All patients were treated with 25 IU/kg PCC, and efficacy was defined as any reduction in or cessation of bleeding episodes and correction of INR before surgery or biopsy. The patients were also evaluated for any adverse effects.

RESULTS: INR decreased significantly in both groups of patients, with no bleeding episodes during or after the study in group 1 and during or after surgery/biopsy in group 2. All patients tolerated the therapy well without any significant adverse effects.

CONCLUSIONS: The efficacy of PCC therapy was satisfactory in this study. PCC therapy in patients with liver disease and patients undergoing surgery or biopsy seems to be effective and safe, and may be a good treatment strategy for these patients, if fresh frozen plasma or vitamin K are not effective.

Keywords: General Surgery; International Normalized Ratio; Liver Diseases; Prothrombin Complex Concentrates

References

  1. Blood. 2010 Aug 12;116(6):878-85 - PubMed
  2. Ann Emerg Med. 2009 Sep;54(3):481-2; author reply 482-3 - PubMed
  3. Clin Med Insights Case Rep. 2011;4:1-6 - PubMed
  4. Eur J Gastroenterol Hepatol. 2003 Jan;15(1):15-20 - PubMed
  5. Neurocrit Care. 2010 Jun;12(3):403-13 - PubMed
  6. J Thromb Haemost. 2010 Dec;8(12):2592-5 - PubMed
  7. Anaesthesia. 2010 Feb;65(2):199-203 - PubMed
  8. Med J Aust. 2004 Nov 1;181(9):492-7 - PubMed
  9. Thromb Res. 1999 Aug 15;95(4 Suppl 1):S71-4 - PubMed
  10. Am J Hematol. 2008 Feb;83(2):137-43 - PubMed
  11. Int J Clin Pract. 2008 Oct;62(10):1614-22 - PubMed
  12. J Thromb Haemost. 2006 May;4(5):967-70 - PubMed
  13. Eur J Anaesthesiol. 2008 Oct;25(10):784-9 - PubMed
  14. Crit Care. 2009;13(6):R191 - PubMed
  15. Ann Hematol. 2012 Aug;91(8):1325-6 - PubMed
  16. J Thromb Haemost. 2006 May;4(5):963-6 - PubMed

Publication Types